


Performance. For life.™

# A powerful solution to peripheral thrombus

improving access and visibility  
for thrombus removal

ANGIOJET®  
**SOLENT™**  
**proxi**

from the Solent family of  
AngioJet peripheral catheters



**MEDRAD**  
Interventional®

# Solent™ Family of AngioJet® Thrombectomy Catheters

Solent. Our family of peripheral catheters offering next-generation technology: improved trackability and enhancements to support better lesion visualization.

## Introducing the Solent Proxi

High-speed saline jets inside the Solent catheter create a powerful low pressure zone that pulls thrombus into the catheter and removes it from the body. Cross-Stream® technology can treat larger arteries without vessel wall contact. The Solent Proxi catheter is compatible with the Ultra Thrombectomy System, 6FR sheath, and 0.035 guidewires—a treatment that works with the standards of your practice.


## Improved Site Access

- Guidewire swapability to allow changing guidewires during a procedure
- Spiral cut proximal shaft offering increased flexibility for reduced kinking
- Distal shaft has hydrophilic coating to reduce drag and ensure smooth delivery


## Improved Visibility

Contrast injection port allows contrast to be delivered directly to the treatment site without disrupting treatment.

## Power Pulse® Delivery



Solent Proxi is Power Pulse enabled for difficult-to-remove thrombus. Power Pulse Delivery enables infusion of medication directly into the clot, saturating the thrombus. The action of Power Pulse Delivery helps disrupt difficult thrombus and prepare it for rapid removal using the Solent Proxi catheter. The result is a rapid and effective means for removing thrombus from deep vein thrombosis.<sup>1</sup>



## Mechanism of Action

Cross-Stream® technology utilizes complex fluid flow patterns to capture and remove thrombus.

## CATHETER SPECIFICATIONS

|                         |             |
|-------------------------|-------------|
| System Compatibility    | Ultra       |
| Vessel Diameter         | ≥ 3mm       |
| Working Length          | 90cm        |
| Shaft Diameter          | 6F          |
| Double Marker Band      | 15 mm       |
| Guidewire Compatibility | OTW 0.035"  |
| Guide Compatibility     | 8F ≥ 0.086" |
| Sheath Compatibility    | 6F          |

## ORDER INFORMATION

### Solent Proxi Thrombectomy Set

|   |            |
|---|------------|
| US part number                              | 109676-001 |
| International part number                   | 109676-002 |
| For use only with the AngioJet Ultra System |            |

<sup>1</sup> Cynamon J, Stein EG, Dym J, et al. A new method for aggressive management of deep vein thrombosis: retrospective study of the power pulse technique. J Vasc Intervent Radiol. June 2006;17:1043-1049.

## AngioJet® Thrombectomy Systems for Peripheral Use

### Indications/Contraindications

AngioJet and AngioJet Ultra Systems are indicated for breaking up and removing thrombus from infra-inguinal peripheral arteries, upper and lower extremity peripheral arteries, upper extremity peripheral veins, iliofemoral and lower extremity veins, A-V access conduits, and for use with the AngioJet Ultra Power Pulse Kit for the control and selective infusion of physician specified fluids, including thrombolytic agents, into the peripheral vascular system. Do not use in patients: who are contraindicated for endovascular procedures, who cannot tolerate contrast media, and in whom the lesion cannot be accessed with the wire guide.

### Warnings and Precautions

The system has not been evaluated for treatment of pulmonary embolism or for use in the carotid or cerebral vasculature. Some AngioJet devices have not been evaluated for use in coronary vasculature. Operation of the catheter may cause embolization of some thrombus and/or thrombotic particulate debris. Cardiac arrhythmias may occur and cardiac rhythm should be monitored during catheter use and appropriate management employed, if needed. Systemic heparinization is advisable to avoid pericatheterization thrombus and acute rethrombosis. Operation of the system causes transient hemolysis. Large thrombus burdens may result in significant hemoglobinemia which should be monitored. Consider hydration, as appropriate.

### Potential Adverse Events

Potential adverse events (in alphabetical order) which may be associated with use of the system include, but are not limited to, the following: abrupt closure of treated vessel, acute myocardial infarction, acute renal failure, bleeding from access site, cerebrovascular accident, death, dissection, embolization (proximal or distal), hematoma, hemolysis, hemorrhage requiring transfusion, hypotension/hypertension, infection at access site, pain, pancreatitis, perforation, pseudoaneurysm, reactions to contrast medium, thrombosis/occlusion, total occlusion of treated vessel, vascular aneurysm, vascular spasm, and vessel wall or valve damage.

Refer to product labeling for device-specific indications, contraindications, warnings/precautions, and adverse events. Rx only. PER – October 2010

Unless otherwise indicated, all trademarks are owned by MEDRAD, INC. or licensed for its use.  
© 2011 MEDRAD, INC. All Rights Reserved.

**MEDRAD**  
Performance. For life.™

**MEDRAD, INC.**  
One Medrad Drive  
Indianola, PA 15051-0780 USA  
Ph: +1 (412) 767-2400  
Other: +1 (800) 633-7231  
Fax: +1 (412) 767-4120  
www.medrad.com

**MEDRAD Europe B.V.**  
P.O. Box 205  
6190 AE Beek  
The Netherlands  
Ph: +31 (0) 43-3585600